anonymous
Guest
anonymous
Guest
Biotechs Are Ripping Following IPAB Ruling
by Jayson Derrick2 hours ago Wed, 22 Jun 2016
http://m.benzinga.com/stock/ACAD
http://m.benzinga.com/stock/BIB
In addition, the U.S. government said that a cost-cutting mechanism known as the Independent Payment Advisory Board (IPAB) is projected to be triggered in 2017.
According to Bloomberg, investors have been "nervously" awaiting on news for the IPAB determination on fears it could have been triggered in 2016 and set in motion reductions in Medicare payments to biotech and pharmaceutical companies.
Biotech Stocks Surging
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) was trading higher by nearly 3 percent, while the SPDR S&P Biotech (ETF) (NYSE: XBI) was trading higher by nearly 2 percent.
The 2x leveraged-ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ: BIB) gained more than 5 percent.
by Jayson Derrick2 hours ago Wed, 22 Jun 2016
http://m.benzinga.com/stock/ACAD
http://m.benzinga.com/stock/BIB
Biotech stocks spiked higher on Wednesday after the U.S. government said that Medicare will be exhausted in 2028, two years sooner than projected last year.
In addition, the U.S. government said that a cost-cutting mechanism known as the Independent Payment Advisory Board (IPAB) is projected to be triggered in 2017.
According to Bloomberg, investors have been "nervously" awaiting on news for the IPAB determination on fears it could have been triggered in 2016 and set in motion reductions in Medicare payments to biotech and pharmaceutical companies.
Biotech Stocks Surging
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) was trading higher by nearly 3 percent, while the SPDR S&P Biotech (ETF) (NYSE: XBI) was trading higher by nearly 2 percent.
The 2x leveraged-ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ: BIB) gained more than 5 percent.